Elekta and ScandiDos Sign Distributor Agreement for Pre-Treatment Verification Tool for Radiation Therapy

CRAWLEY, England, May 26, 2011 -

Elekta and ScandiDos AB have entered into a non-exclusive global
agreement to distribute ScandiDos's Delta4PT quality assurance (QA) tool.
Delta4PT can be used with Intensity Modulated Radiation Therapy (IMRT) and
Volumetric Modulated Arc Therapy (VMAT) techniques to provide complete
pre-treatment QA that ensures that the dose prescribed in treatment plans is
delivered accurately and safely to patients.

"We're very pleased that Elekta, a true innovator and leader in the
radiation oncology industry recognized the value of our ScandiDos Delta4PT QA
solution," says Gorgen Nilsson, CEO at ScandiDos. "We hope this is the
beginning of an ongoing relationship with Elekta and its customers as they
strive to make radiation therapy the safest, most effective tool in the fight
against cancer and other serious diseases."

Delta4PT, used to verify IMRT and arc therapy delivery techniques since
2006, enables clinicians to verify dose delivery without compromises, in 3D;
instantly analyze and approve plans; evaluate the clinical significance of
deviation; and identify the cause of deviations. The benefits are improved
efficiency by increasing the volume of patients that can be treated as well
as enhanced verification accuracy - enabling more qualified QA decisions to
be made.

The agreement will make Delta4PT accessible to the Elekta customer
network, further complementing the Elekta QA solutions portfolio and widening
the breadth of choices for its customers.

"As an open source, vendor neutral company, our partnership with
ScandiDos ensures that our customers can select QA solutions that best meet
their needs and clinical resources," says Brett North, Marketing Director,
Oncology at Elekta.

About Elekta

Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning systems
for radiation therapy and radiosurgery, as well as workflow enhancing
software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to both
healthcare providers and patients, Elekta aims to improve, prolong and even
save patient lives, making the future possible.

Today, Elekta solutions in oncology and neurosurgery are used in over
5,000 hospitals globally, and every day more than 100,000 patients receive
diagnosis, treatment or follow-up with the help of a solution from the Elekta
Group.

Elekta employs around 2,500 employees globally. The corporate headquarter
is located in Stockholm, Sweden, and the company is listed on the Nordic
Exchange under the ticker EKTAb. For more information about Elekta, please
visit www.elekta.com.

About ScandiDos

ScandiDos is the innovative company that introduced the new QA standard
in advanced radiotherapy by moving into the era of 3D and 4D volumetric
dosimetry. Founded in 2002 by a group of highly experienced physicists and
engineers, ScandiDos grew out of a recognized need for practical clinical
solutions for new advanced radiation therapy technologies. ScandiDos mission
is to provide complete dosimetry solutions that enable clinics around the
world to implement new treatment modalities satisfying the demand on accuracy
in dose verification and patient through-put. ScandiDos has offices in
Uppsala, Sweden and Madison, WI, USA and is a privately held company. For
more information visit www.scandidos.com.

Stina Thorman, Vice President Corporate Communications, Elekta AB, +46-8-587-254-37, stina.thorman at elekta.com, Time zone: CET: Central European; Michelle Lee, Director, Global Public Relations and Brand Management, Elekta, +1-770-670-2447, michelle.lee at elekta.com, Time zone: EDT: Eastern Daylight